Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 52
Filtrar
1.
Int. j. morphol ; 40(6): 1481-1483, dic. 2022.
Artigo em Inglês | LILACS | ID: biblio-1421822

RESUMO

SUMMARY: The lateral pterygoid muscle (LPM) is intimately related with the temporomandibular joint (TMJ), playing an important role in its physiology. This makes it of interest to researchers who investigate temporomandibular disorders. The literature indicates that anatomical variations exist in the insertion of the superior fascicle of the LPM. Imaging and cadaver studies have revealed that the LPM may present an accessory fascicle. The study object was to carry out macroscopic analysis of the LPM, examining the origin and insertion of its superior and inferior fascicles. The study used 38 half-heads of adult individuals fixed in formaldehyde 10 %. To carry out macroscopic analysis of the LPM, an initial incision was made along the lower margin of the zygomatic arch; the origin of the masseter muscle was then dissected, separating its insertion on the lateral face of the mandibular ramus and retracting the muscle to posteroinferior. Two incisions were made on the zygomatic arch and the insertion of the temporal muscle on the coronoid process was identified with dissection pincers; it was dissected to gain access to the infratemporal fossa and the two fascicles of the LPM. The superior fascicle (SF) originated on the infratemporal face of the greater wing of the sphenoid, and on the superior third of the lateral face of the lateral lamina of the pterygoid process of the sphenoid in 26 samples. In 12 samples, it originated on the greater wing of the sphenoid and the infratemporal crest of the sphenoid. Type I insertion was found in 20 samples, Type II in 6 samples and Type III in 12 samples. In all the samples analysed, the inferior fascicle (IF) originated on the inferior two thirds of the lateral face of the lateral lamina of the pterygoid process and on the lateral face of the pyramidal process of the palatine, with insertion on the pterygoid fovea. The accessory fascicle (AF) of the LPM was present in 6 samples. The AF originated on the greater wing of the sphenoid in 2 cases and inferior to the superior fascicle in 4 cases; its insertion was on the capsular disc complex in all cases. The results obtained in our study contribute anatomical data on the LPM in Brazilian adult individuals, with evaluation of its insertion points.


El músculo pterigoideo lateral (MPL) presenta íntima relación con la articulación temporomandibular (ATM) y desempeña un rol importante en la fisiología de esta articulación, despertando el interés de investigadores que se dedican al estudio de los trastornos temporomandibulares. La literatura señala que existen variaciones anatómicas del MPL, con respecto a la inserción del fascículo superior. Los estudios cadavéricos e imagenológicos han revelado que el MPL puede presentar un fascículo accesorio. El objetivo del estudio fue realizar un análisis macroscópico del MPL, examinando el origen e inserción de sus fascículos superior e inferior. Se utilizaron 38 hemicabezas de individuos adultos fijadas en formaldehído al 10 %. Para realizar el análisis macroscópico del MPL se realizó inicialmente una incisión a lo largo del margen inferior del arco cigomático, luego se seccionó el origen del músculo masétero separando su inserción en la cara lateral de la rama de la mandíbula, retrayendo al músculo en sentido posteroinferior. Se hicieron dos cortes en el arco cigomático y con pinzas de disección se identificó la inserción del músculo temporal en el proceso coronoides, el cual se seccionó para ingresar a la fosa infratemporal y acceder a ambos fascículos del MPL. El fascículo superior (FS) del MPL se originó en la cara infratemporal del ala mayor del esfenoides y en el tercio superior de la cara lateral de la lámina lateral del proceso pterigoides del esfenoides en 26 muestras. En 12 muestras se originó en el ala mayor del esfenoides y cresta infratemporal del esfenoides. Con relación a su inserción, se encontró el Tipo I en 20 muestras; el Tipo II en 6 muestras y el Tipo III en 12 muestras. En todas las muestras analizadas el origen del fascículo inferior (FI) del MPL fue en los dos tercios inferiores de la cara lateral de la lámina lateral del proceso pterigoides y en la cara lateral del proceso piramidal del palatino insertándose en la fóvea pterigoidea. El fascículo accesorio (FA) del MPL estuvo presente en 6 muestras. El FA se originó en el ala mayor del esfenoides en 2 casos e inferior al fascículo superior en 4 casos y su inserción, en el complejo disco capsular en todos los casos. Mediante los resultados obtenidos en nuestro estudio estamos aportando datos anatómicos en relación al MPL en individuos brasileños adultos, evaluándolo con respecto a sus lugares de inserción.


Assuntos
Humanos , Adulto , Músculos Pterigoides/anatomia & histologia , Variação Anatômica , Cadáver
5.
Int. j. morphol ; 39(5): 1270-1273, oct. 2021. tab
Artigo em Inglês | LILACS | ID: biblio-1385501

RESUMO

SUMMARY: The lateral pterygoid muscle (LPM) is one of the muscles involved in jaw movements, and is therefore of great importance in the physiology of the temporomandibular joint. This muscle has classically been considered to have two heads, superior and inferior, however previous studies have indicated the presence of a third head (TH). The object of this research was therefore to evaluate, through a study in cadavers, the presence of the third head of the LPM and its relation with the joint disc of the TMJ in adult individuals. The study used 30 half-skulls of adult individuals, 11 right side and 19 left side. The number of heads on each LPM was analysed, with the length and thickness of each. The Chi-squared, Mann-Whitney U, Kruskall-Wallis and Spearman's correlation coefficient tests were applied, with a significance threshold of 5 %. The TH of the LPM was present in 20 % of the samples. Statistically significant differences were found in the thickness of the superior head (SH) vs. the inferior head (IH) (p<0.001) and between TH vs. SH and TH vs. IH (p=0.010). No correlation was found between the thickness of the heads or in their lengths. The LPM most frequently presents two heads, superior and inferior. The TH is an anatomical variation that may be present in 20 % of cases. The IH usually presents the greatest thickness. The use of cadavers is a good method for analysing the presence of the TH and the morphometry of the various heads of the LPM.


RESUMEN: El músculo pterigoideo lateral (MPL) es uno de los músculos involucrados en los movimientos mandibulares y por consiguiente tiene una gran importancia en la fisiología de la articulación temporomandibular (ATM). Clásicamente se ha considerado como un músculo que presenta dos cabezas, una superior y otra inferior, sin embargo estudios anteriores han señalado la presencia de una tercera cabeza (TC). El objetivo fue evaluar, mediante estudio en cadáveres, la presencia de la tercera cabeza del MPL y su relación con el disco articular de la ATM de individuos adultos. Se utilizaron 30 hemicabezas de individuos adultos, 11 del lado derecho y 19 en el lado izquierdo. Se analizó el número de cabezas, longitud y grosor de cada cabeza. Se aplicaron las pruebas de chi-cuadrado, U-Mann-Whitney, Kruskall-Walis y coeficiente de correlación de Spearman, con umbral de significación de 5 %. La TC del MPL estuvo presente en 20 % de las muestras. Se encontraron diferencias estadísticas significativas para el grosor del la cabeza superior (CS) vs. cabeza inferior (CI) (p<0,001) y entre TC vs. CS y TC vs. CI (p=0,010). No se encontró correlación entre el grosor de las cabezas o para la longitud de las cabezas. El MPL se presenta más frecuentemente con dos cabezas, una superior y otra inferior. La TC es una variación anatómica que puede estar presente en un 20 % de los casos. La CI suele ser la que presenta mayor grosor. En cuanto a los métodos para análisis de presencia de la TC y morfometría de las distintas cabezas del MPL el uso de cadáveres representa una buena alternativa.


Assuntos
Humanos , Adulto , Músculos Pterigoides/anatomia & histologia , Variação Anatômica , Cadáver
6.
Rev Assoc Med Bras (1992) ; 67(3): 474-478, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34468617

RESUMO

INTRODUCTION: The rapid advance of Coronavirus disease 2019 (Covid-19) has led to the incessant search for therapeutic and prophylactic measures to fight the pandemic. Because it is a viral infection, the safest long-term prophylactic form, in addition to social distance and hygiene, is the vaccine. OBJECTIVE: Thus, this study aimed at conducting a review of the efficacy and landscape of Covid-19 vaccines. METHODS: The following electronic databases were used MEDLINE via PubMed, SCIELO, LILACS, NEJM, and Clinical Trials. Our study includes the 7 vaccines (phase 3) that reported an efficacy rate for Covid-19, including characteristics inherent to each one of them. RESULTS: Preliminary studies have shown that, although an efficacy ≥70% is necessary to eliminate the infection, a prophylactic vaccine with efficacy <70% will still have an important impact and can contribute to the elimination of the virus, provided that appropriate measures of social distancing remain. CONCLUSIONS: The effectiveness of the vaccines obtained in this study varied between 50.38 and 95%, data that may represent a reduction in serious cases, hospitalizations, sequels, and deaths caused by Covid-19, respecting the panorama presented in this article.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Humanos , Pandemias , Distanciamento Físico , SARS-CoV-2
8.
Rev Assoc Med Bras (1992) ; 66(10): 1444-1448, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33174941

RESUMO

OBJECTIVE: To conduct a review of articles which have evaluated the relationship between vitamin D and cardioprotection in adult. METHODS: A literature search was performed in the Pubmed and Scielo databases. The results were extracted from primary and secondary sources and will be presented in the form of a bibliographic review. RESULTS: Twenty-three articles were identified from the electronic search that reported on physiological mechanisms relating the vitamin D axis and the cardiovascular system through receptors. Of the ten studies that evaluated the therapeutic effect of vitamin D in cardiovascular diseases, none reported significant results. CONCLUSION: The articles assessed in this review did not demonstrate a cardioprotective effect of vitamin D, despite the epidemiological correlation of vitamin D deficiency with a higher prevalence of cardiovascular diseases.


Assuntos
Deficiência de Vitamina D , Adulto , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Humanos , Prevalência , Vitamina D , Deficiência de Vitamina D/complicações , Deficiência de Vitamina D/tratamento farmacológico , Deficiência de Vitamina D/prevenção & controle , Vitaminas/uso terapêutico
9.
Rev. Assoc. Med. Bras. (1992) ; 66(10): 1444-1448, Oct. 2020. tab, graf
Artigo em Inglês | Sec. Est. Saúde SP, LILACS | ID: biblio-1136162

RESUMO

SUMMARY OBJECTIVE: To conduct a review of articles which have evaluated the relationship between vitamin D and cardioprotection in adult. METHODS: A literature search was performed in the Pubmed and Scielo databases. The results were extracted from primary and secondary sources and will be presented in the form of a bibliographic review. RESULTS: Twenty-three articles were identified from the electronic search that reported on physiological mechanisms relating the vitamin D axis and the cardiovascular system through receptors. Of the ten studies that evaluated the therapeutic effect of vitamin D in cardiovascular diseases, none reported significant results. CONCLUSION: The articles assessed in this review did not demonstrate a cardioprotective effect of vitamin D, despite the epidemiological correlation of vitamin D deficiency with a higher prevalence of cardiovascular diseases.


Assuntos
Humanos , Adulto , Deficiência de Vitamina D/complicações , Deficiência de Vitamina D/prevenção & controle , Deficiência de Vitamina D/tratamento farmacológico , Vitamina D , Vitaminas/uso terapêutico , Doenças Cardiovasculares/prevenção & controle , Doenças Cardiovasculares/epidemiologia , Prevalência
10.
Rev Assoc Med Bras (1992) ; 66(6): 838-841, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32696862

RESUMO

The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, SCIELO, LILACS, and PUBMED. On May 1, Remdesivir received emergency use authorization from the Food and Drug Administration. Remdesivir is currently the most promising molecule in the treatment of COVID-19, taking into account its broad antiviral spectrum (considering the genetic sequences of the virus, it is expected to maintain activity against SARS-CoV-2). There is in vitro and in vivo information available for coronaviruses, as well as an extensive clinical safety database (from a clinical trial of the Ebola virus and in the context of the Monitored Emergency Use of Unregistered and Investigational Interventions - MEURI). Further studies are relevant as available data on the efficacy and safety of Remdesivir against SARS-nCoV-2 are limited.


Assuntos
Monofosfato de Adenosina/análogos & derivados , Alanina/análogos & derivados , Antivirais , Infecções por Coronavirus , Pandemias , Pneumonia Viral , Monofosfato de Adenosina/uso terapêutico , Alanina/uso terapêutico , Antivirais/uso terapêutico , Betacoronavirus , COVID-19 , Infecções por Coronavirus/tratamento farmacológico , Humanos , Pneumonia Viral/tratamento farmacológico , SARS-CoV-2 , Tratamento Farmacológico da COVID-19
11.
Rev Assoc Med Bras (1992) ; 66(3): 370-374, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32520160

RESUMO

The present study aimed to review the epidemiology, clinical manifestation, laboratory diagnosis, treatment, and future perspectives related to COVID-19 infections. The following electronic databases were used searched: MEDLINE, SCIELO, and LILACS. It became clear that COVID-19 infections occur through exposure to the virus, and both the immunosuppressed and healthy population appear susceptible. The clinical course of COVID-19 is still not clear, although the SARS-CoV-2 infection seems to develop with mild, influenza-like symptoms in the vast majority of subjects, i.e., 10%-15% of COVID-19 patients. Since rRT-PCR tests serve as the gold standard method to confirm a SARS-CoV-2 infection, false-negative results could hinder the prevention and control of the epidemic, particularly considering the test plays a key role in the decision for continued isolated medical observation or discharge. Our findings also indicate that a radical increase in the identification and isolation of currently undocumented infections would be needed to fully control SARS-CoV2.


Assuntos
Betacoronavirus , Infecções por Coronavirus , Pandemias , Pneumonia Viral , COVID-19 , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/terapia , Humanos , Pneumonia Viral/diagnóstico , Pneumonia Viral/epidemiologia , Pneumonia Viral/terapia , SARS-CoV-2 , Análise Espacial
12.
Rev. Assoc. Med. Bras. (1992) ; 66(6): 838-841, June 2020. graf
Artigo em Inglês | Sec. Est. Saúde SP, LILACS | ID: biblio-1136277

RESUMO

SUMMARY The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, SCIELO, LILACS, and PUBMED. On May 1, Remdesivir received emergency use authorization from the Food and Drug Administration. Remdesivir is currently the most promising molecule in the treatment of COVID-19, taking into account its broad antiviral spectrum (considering the genetic sequences of the virus, it is expected to maintain activity against SARS-CoV-2). There is in vitro and in vivo information available for coronaviruses, as well as an extensive clinical safety database (from a clinical trial of the Ebola virus and in the context of the Monitored Emergency Use of Unregistered and Investigational Interventions - MEURI). Further studies are relevant as available data on the efficacy and safety of Remdesivir against SARS-nCoV-2 are limited.


RESUMO O agente etiológico da COVID-19, que causa doenças respiratórias graves, como pneumonia e insuficiência pulmonar, foi confirmado como um novo coronavírus, agora conhecido como coronavirus de síndrome respiratória aguda grave 2 (SARS-CoV-2). Não existem atualmente medicamentos autorizados para o tratamento de COVID-19, nem estão também autorizadas quaisquer vacinas. Assim, o estudo teve como objetivo realizar uma revisão sobre a utilização de Remdesivir em pacientes com COVID-19. As seguintes bases de dados eletrônicas foram utilizadas MEDLINE, SCIELO, LILACS e PUBMED. Em primeiro de maio, o Redemsivir recebeu autorização de uso de emergência da Food and Drug Administration. Remdesivir é presentemente a molécula promissora no tratamento da COVID-19 tendo em conta o seu largo espetro antiviral (considerando as sequências genéticas do vírus, é expectável que mantenha atividade contra o SARS-CoV-2). A informação in vitro e in vivo está disponível para os coronavírus, assim como a extensiva base de dados de segurança clínica (proveniente de ensaio clínico do vírus Ebola e no contexto do Monitored Emergency Use of Unregistered and Investigational Interventions - MEURI). A realização de novos estudos torna-se relevantes uma vez que os dados disponíveis são limitados sobre eficácia e segurança do Remdesivir contra SARS-nCoV-2.


Assuntos
Humanos , Antivirais/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Monofosfato de Adenosina/análogos & derivados , Infecções por Coronavirus/tratamento farmacológico , Alanina/análogos & derivados , Pandemias , Monofosfato de Adenosina/uso terapêutico , Infecções por Coronavirus , Alanina/uso terapêutico , Betacoronavirus
13.
Rev. Assoc. Med. Bras. (1992) ; 66(3): 370-374, Mar. 2020. tab, graf
Artigo em Inglês | Sec. Est. Saúde SP, LILACS | ID: biblio-1136191

RESUMO

SUMMARY The present study aimed to review the epidemiology, clinical manifestation, laboratory diagnosis, treatment, and future perspectives related to COVID-19 infections. The following electronic databases were used searched: MEDLINE, SCIELO, and LILACS. It became clear that COVID-19 infections occur through exposure to the virus, and both the immunosuppressed and healthy population appear susceptible. The clinical course of COVID-19 is still not clear, although the SARS-CoV-2 infection seems to develop with mild, influenza-like symptoms in the vast majority of subjects, i.e., 10%-15% of COVID-19 patients. Since rRT-PCR tests serve as the gold standard method to confirm a SARS-CoV-2 infection, false-negative results could hinder the prevention and control of the epidemic, particularly considering the test plays a key role in the decision for continued isolated medical observation or discharge. Our findings also indicate that a radical increase in the identification and isolation of currently undocumented infections would be needed to fully control SARS-CoV2.


RESUMO O presente estudo teve como objetivo realizar uma revisão sobre epidemiologia, manifestações clínicas, diagnóstico laboratorial, tratamento e perspectivas futuras relacionados à infecção pelo COVID-19. As seguintes bases de dados eletrônicas foram utilizadas MEDLINE, SCIELO e LILACS. Ficou claro que a infecção pelo COVID-19 ocorre por exposição ao vírus, e tanto a população imunossupressora quanto a normal parecem suscetíveis. O curso clínico do COVID-19 ainda não está claro, embora a infecção por SARS-CoV-2 pareça ocorrer com sintomas leves e semelhantes à gripe na grande maioria dos indivíduos, em 10%-15% dos pacientes com COVID-19. Uma vez que os testes rRT-PCR servem como o método padrão-ouro para confirmar a infecção do SARS-CoV-2, os resultados falso-negativos podem dificultar a prevenção e o controle da epidemia, particularmente quando este teste desempenha um papel de referência fundamental na decisão da necessidade de observação médica isolada ou alta. Nossos achados também indicam que seria necessário um aumento radical na identificação e isolamento de infecções não documentadas atualmente para controlar totalmente o SARS-CoV2.


Assuntos
Humanos , Pneumonia Viral/diagnóstico , Pneumonia Viral/terapia , Pneumonia Viral/epidemiologia , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/terapia , Infecções por Coronavirus/epidemiologia , Pandemias , Betacoronavirus , Infecções por Coronavirus , Análise Espacial
14.
Arq. bras. oftalmol ; 82(5): 436-445, Sept.-Oct. 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1019427

RESUMO

ABSTRACT This systematic review aimed to assess the effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes in Universidade Federal de Alagoas (PROSPERO 2018 CRD42018089933). Online databases were searched (LILACS, EMBASE, MEDLINE, and CENTRAL) from inception to April 2018; references from included papers were also searched. The following keywords were used: lubricants OR artificial tears OR artificial tears, lubricants AND dry eye OR dry eye syndrome OR syndromes, dry eye OR dry eyes. Among the 2028 electronic search results, 29 full papers were retrieved and four were considered relevant. The number of participants from these studies ranged from 15 to 76. Meta-analysis was possible for the following outcomes: score of symptoms according to the Ocular Surface Disease Index - Allergan (OSDI), tear secretion rate using the Schirmer test, tear evaporation rate using the tear film breakup time test, burning, foreign body sensation, and photophobia. No statistically significant difference was observed between the two groups, and no side effects were attributed to the interventions. Evidence proving that preservative-free artificial tears are more effective than preserved artificial tears is lacking.


RESUMO Esta revisão sistemática teve como objetivo avaliar a eficácia do uso de lágrimas artificiais sem conservantes em comparação com lubrificantes preservados no tratamento do olho seco na Universidade Federal de Alagoas (PROSPERO 2018 CRD42018089933). As bases de dados online foram pesquisadas (LILACS, EMBASE, MEDLINE e CENTRAL) desde o início até abril de 2018; referências de artigos incluídos também foram pesquisadas. Foram utilizados os seguintes descritores: lubrificantes OU lágrimas artificiais OU lágrimas artificiais, lubrificantes E olho seco OU síndrome do olho seco OU síndromes, olho seco OU olhos secos. Dos 2028 resultados de busca eletrônica, 29 artigos completos foram recuperados, e quatro foram considerados relevantes. O número de participantes desses estudos variou de 15 e 76. A meta-análise foi possível para as seguintes variáveis: escore de desfecho dos sintomas de acordo com o Índice de Doença da Superfície Ocular - Allergan (OSDI), taxa de secreção lacrimal pelo teste de Schirmer, taxa de evaporação lacrimal usando o teste de tempo de ruptura do filme lacrimal, queimação, sensação de corpo estranho e fotofobia. Nenhuma diferença estatisticamente significativa foi observada entre os dois grupos, e nenhum efeito adverso foi atribuído às intervenções. Evidências provando que as lágrimas artificiais sem conservantes são mais eficazes do que as lágrimas artificiais preservadas estão faltando.


Assuntos
Humanos , Masculino , Feminino , Soluções Oftálmicas/farmacologia , Conservantes Farmacêuticos/farmacologia , Síndromes do Olho Seco/tratamento farmacológico , Lubrificantes Oftálmicos/farmacologia , Soluções Oftálmicas/uso terapêutico , Conservantes Farmacêuticos/uso terapêutico , Lágrimas , Viés , Lubrificantes Oftálmicos/uso terapêutico
15.
Arq Bras Oftalmol ; 82(5): 436-445, 2019 09 09.
Artigo em Inglês | MEDLINE | ID: mdl-31508669

RESUMO

This systematic review aimed to assess the effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes in Universidade Federal de Alagoas (PROSPERO 2018 CRD42018089933). Online databases were searched (LILACS, EMBASE, MEDLINE, and CENTRAL) from inception to April 2018; references from included papers were also searched. The following keywords were used: lubricants OR artificial tears OR artificial tears, lubricants AND dry eye OR dry eye syndrome OR syndromes, dry eye OR dry eyes. Among the 2028 electronic search results, 29 full papers were retrieved and four were considered relevant. The number of participants from these studies ranged from 15 to 76. Meta-analysis was possible for the following outcomes: score of symptoms according to the Ocular Surface Disease Index - Allergan (OSDI), tear secretion rate using the Schirmer test, tear evaporation rate using the tear film breakup time test, burning, foreign body sensation, and photophobia. No statistically significant difference was observed between the two groups, and no side effects were attributed to the interventions. Evidence proving that preservative-free artificial tears are more effective than preserved artificial tears is lacking.


Assuntos
Síndromes do Olho Seco/tratamento farmacológico , Lubrificantes Oftálmicos/farmacologia , Soluções Oftálmicas/farmacologia , Conservantes Farmacêuticos/farmacologia , Viés , Feminino , Humanos , Lubrificantes Oftálmicos/uso terapêutico , Masculino , Soluções Oftálmicas/uso terapêutico , Conservantes Farmacêuticos/uso terapêutico , Lágrimas
16.
Braz J Anesthesiol ; 69(5): 493-501, 2019.
Artigo em Português | MEDLINE | ID: mdl-31521383

RESUMO

BACKGROUND AND OBJECTIVES: Low back pain is a prevalent disease in the adult population, whose quality of life is considerably affected. In order to solve this problem, several therapies have been developed, of which ozone therapy is an example. Our objective in this study was to determine the effectiveness of ozone therapy for lumbar pain relief in adult patients compared to other therapies (steroid and placebo). METHOD: We used randomized clinical trials to compare the effectiveness of ozone and other therapies for lumbar pain relief in adults (Prospero: CRD42018090807). Two independent reviewers searched the Medline (1966-April/2018), Scopus (2011-May/2018), Lilacs (1982-May/2018), and Embase (1974-March/2018) databases. We use the terms ozone and pain as descriptors. The primary variable was pain relief and the secondary ones were complication, degree of satisfaction, quality of life, and recurrence of pain. RESULTS: Of the 779 identified articles, six selected clinical trials show that ozone therapy is more effective for lumbar pain relief; however, they were mostly classified as having a high or uncertain risk of bias (Cochrane Handbook). The meta-analysis regarding the effectiveness of pain relief did not show a significant difference between groups in the three-month period (RR = 1.98, 95% CI: 0.46-8.42, p = 0.36; 366 participants). It also showed greater effectiveness of the ozone therapy at six months compared to other therapies (steroid and placebo) (RR = 2.2, 95% CI: 1.87-2.60, p < 0.00001; 717 participants). CONCLUSIONS: The systematic review has shown that ozone therapy used for six months for lumbar pain relief is more effective than other therapies; however, this result is not definitive as data from studies with moderate to high risk of bias were used.


Assuntos
Dor Lombar/tratamento farmacológico , Ozônio/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Humanos , Resultado do Tratamento
17.
Rev. bras. anestesiol ; 69(3): 299-306, May-June 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1013417

RESUMO

Abstract Background and objective: The systematic review of randomized clinical trials is crucial to assess the safety and effectiveness of intermediate procedures. The objective of this article is to present a tutorial for the planning and execution of systematic review and meta-analysis of randomized clinical trial studies. Method: The systematic literature review is the type of research that organizes, criticizes, and integrates available evidence published in the health field. Systematization leads to less bias, however, the quality of systematic reviews may not always be perceived due to the way it is described in the articles. The information disclosed in the articles is not always free of bias. The steps for carrying out a systematic review include design, protocol registration, implementation, mathematical analysis of results, and dissemination. PRISMA statement has improved the quality of systematic review reports by providing a list of items to be described, and this article emphasizes the key steps for performing a systematic review of interventions. Conclusion: The evidence generated through a systematic review can provide the clinician with greater confidence in decision making at the moment of clinical practice and optimize the benefits to his patients, serving as a tool to assist managers in making decisions regarding the implementation of new strategies for the health of the population.


Resumo Justificativa e objetivo: A revisão sistemática de ensaios clínicos randomizados é crucial para avaliar a segurança e a efetividade das intervenções médicas. O objetivo deste artigo é apresentar um tutorial para o planejamento e execução de revisões sistemáticas e metanálises de estudos de ensaios clínicos randomizados. Método: A revisão sistemática da literatura é o tipo de pesquisa que organiza, critica e integra as evidências disponíveis publicadas na áera da saúde. A sistematização leva a menos vieses, entretanto a qualidade das revisões sistemáticas nem sempre pode ser percebida devido à forma como têm sido descritas nos artigos. A informação divulgada nos artigos nem sempre está livre de vieses. Os passos para a revisão sistemática incluem o delineamento, o registro do protocolo, a execução, a análise matemática dos resultados e a divulgação. O PRISMA statement melhorou a qualidade dos relatos das revisões sistemáticas, pois fornece uma lista de itens a serem descritos, e este artigo enfatiza os principais passos para a execução de uma revisão sistemática de intervenção. Conclusão: A evidência gerada por meio de uma revisão sistemática pode propiciar ao médico maior confiança na tomada de decisões no momento da prática clínica, aprimorar os benefícios aos seus pacientes e servir como ferramenta para auxiliar os gestores na tomada de decisões quanto à implantação de novas estratégias em prol da saúde da população.


Assuntos
Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Revisões Sistemáticas como Assunto , Anestesia/métodos , Metanálise como Assunto , Anestesiologia
18.
Braz J Anesthesiol ; 69(3): 299-306, 2019.
Artigo em Português | MEDLINE | ID: mdl-30717891

RESUMO

BACKGROUND AND OBJECTIVE: The systematic review of randomized clinical trials is crucial to assess the safety and effectiveness of intermediate procedures. The objective of this article is to present a tutorial for the planning and execution of systematic review and meta-analysis of randomized clinical trial studies. CONTENT: The systematic literature review is the type of research that organizes, criticizes, and integrates available evidence published in the health field. Systematization leads to less bias, however, the quality of systematic reviews may not always be perceived due to the way it is described in the articles. The information disclosed in the articles is not always free of bias. The steps for carrying out a systematic review include design, protocol registration, implementation, mathematical analysis of results, and dissemination. PRISMA statement has improved the quality of systematic review reports by providing a list of items to be described, and this article emphasizes the key steps for performing a systematic review of interventions. CONCLUSION: The evidence generated through a systematic review can provide the clinician with greater confidence in decision making at the moment of clinical practice and optimize the benefits to his patients, serving as a tool to assist managers in making decisions regarding the implementation of new strategies in favor of the public health.


Assuntos
Anestesia , Metanálise como Assunto , Revisões Sistemáticas como Assunto , Humanos , Anestesia/métodos , Anestesiologia , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos
19.
Rev. bras. ginecol. obstet ; 41(2): 104-115, Feb. 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1003533

RESUMO

Abstract Diabetes during pregnancy has been linked to unfavorable maternal-fetal outcomes. Human insulins are the first drug of choice because of the proven safety in their use. However, there are still questions about the use of insulin analogs during pregnancy. The objective of the present study was to determine the effectiveness of insulin analogs compared withhuman insulin in the treatment of pregnant women with diabetes througha systematic review withmeta-analysis. The search comprised the period since the inception of each database until July 2017, and the following databases were used:MEDLINE, CINAHL, EMBASE, ISIWeb of Science, LILACS, Scopus, SIGLE andGoogle Scholar.We have selected 29 original articles: 11 were randomized clinical trials and 18 were observational studies.We have explored data from 6,382 participants. All of the articles were classified as having an intermediate to high risk of bias. The variable that showed favorable results for the use of insulin analogs was gestational age, with a mean difference of - 0.26 (95 % confidence interval [CI]: 0.03-0.49; p = 0.02), but with significant heterogeneity (Higgins test [I2] = 38%; chi-squared test [χ2] = 16.24; degree of freedom [DF] = 10; p = 0.09). This result, in the clinical practice, does not compromise the fetal well-being, since all babies were born at term. There was publication bias in the gestational age and neonatal weight variables. To date, the evidence analyzed has a moderate-to-high risk of bias and does not allow the conclusion that insulin analogs are more effective when compared with human insulin to treat diabetic pregnant women.


Resumo Diabetes durante a gestação tem sido relacionado a desfechos materno-fetais desfavoráveis. As insulinas humanas são a primeira escolha medicamentosa, devido à comprovada segurança no seu uso. Entretanto, ainda há questionamentos sobre o uso dos análogos da insulina na gestação. O objetivo do presente estudo foi determinar a efetividade dos análogos da insulina comparados às insulinas humanas no tratamento de gestantes com diabetes por meio de uma revisão sistemática com metanálise. A busca compreendeu desde o início de cada base de dados até julho de 2017, e foi realizada nos seguintes bancos de dados: MEDLINE, CINAHL, EMBASE, ISI Web of Science, LILACS, Scopus, SIGLE e Google Scholar. Selecionamos 29 artigos originais, sendo 11 ensaios clínicos randomizados e 18 estudos observacionais. Exploramos dados de 6.382 participantes. Todos os artigos foram classificados como sendo de intermediário a alto risco de viés. A variável que demonstrou resultado favorável ao uso dos análogos da insulina foi idade gestacional, com uma diferençamédia de - 0.26 (95% índice de confiança [IC]: 0.03-0.49; p = 0.02), porém com heterogeneidade significativa (teste de Higgins [I2] = 38%; teste do qui quadrado [χ2] =16.24; graus de liberdade [GL] =10; p = 0.09). Esse resultado, na prática clínica, não compromete o bem-estar fetal, uma vez que todos os bebês nasceram a termo. Houve viés de publicação nas variáveis idade gestacional e peso neonatal. Até o momento, as evidências analisadas possuem um risco de viés moderado a elevado e não permitem concluir que os análogos da insulina sejam mais efetivos em comparação às insulinas humanas para tratar gestantes diabéticas.


Assuntos
Humanos , Feminino , Gravidez , Diabetes Gestacional/tratamento farmacológico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Cuidado Pré-Natal/métodos , Peso ao Nascer , Macrossomia Fetal/etiologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Aborto Espontâneo/etiologia , Idade Gestacional , Resultado do Tratamento , Estudos Observacionais como Assunto , Insulina Aspart/uso terapêutico , Insulina Lispro/uso terapêutico , Insulina Glargina/uso terapêutico , Hipoglicemia/induzido quimicamente , Insulina/análogos & derivados
20.
Rev Assoc Med Bras (1992) ; 63(7): 636-641, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28977090

RESUMO

INTRODUCTION: Diabetes mellitus is one of the most common chronic diseases in the world, with high morbidity and mortality rates, resulting in a greatly negative socioeconomic impact. Although there are several classes of oral antidiabetic agents, most of the patients are outside the therapeutic goal range. OBJECTIVE: To review the use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus, focusing on their favorable and unfavorable effects, as well as on cardiovascular profile. METHOD: A literature search on Pubmed database was performed using the following keywords: "SGLT-2 inhibitors," "dapagliflozin," "empagliflozin," "canagliflozin." RESULTS: SGLT-2 inhibitors are a class of oral antidiabetic drugs directed to the kidney. Their mechanism of action is to reduce blood glucose by inducing glycosuria. Extra-glycemic benefits have been described, such as weight loss, decline in blood pressure and levels of triglycerides and uric acid, and they can slow the progression of kidney disease. Genitourinary infections are the main side effects. There is a low risk of hypotension and hypoglycemia. Diabetic ketoacidosis is a serious adverse effect, although rare. Empagliflozin has already had its cardiovascular benefit demonstrated and studies with other drugs are currently being performed. CONCLUSION: SGLT-2 inhibitors are a new treatment option for type 2 diabetes mellitus, acting independently of insulin. They have potential benefits other than the reduction of blood glucose, but also carry a risk for adverse effects.


Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Inibidores do Transportador 2 de Sódio-Glicose , Compostos Benzidrílicos/uso terapêutico , Glicemia/efeitos dos fármacos , Canagliflozina/uso terapêutico , Glucosídeos/uso terapêutico , Humanos , Hipoglicemiantes/efeitos adversos , Rim/efeitos dos fármacos , Transportador 2 de Glucose-Sódio
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...